Lack of bioequivalence of levofloxacin when coadministered with a mineral-fortified breakfast of juice and cereal

Journal of Clinical Pharmacology

Volumn 43, Issue 9, 2003, Pages 990-995

  Amsden, Guy W ^a   Whitaker, Anne Marie ^b   Johnson, Patrick W ^b  

^a BASSETT RESEARCH INSTITUTE   (United States)

^b NONE

Author keywords

Bioequivalence; Drug interactions; Levofloxacin; Pharmacokinetics

Indexed keywords

CALCIUM; ION; IRON; LEVOFLOXACIN; MINERAL; MULTIVALENT ION; UNCLASSIFIED DRUG; WATER; ZINC;

ADULT; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CEREAL; DIET RESTRICTION; DIET SUPPLEMENTATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG HALF LIFE; FEMALE; FOOD DRUG INTERACTION; FRUIT JUICE; HEADACHE; HUMAN; MALE; MEAL; MILK; NAUSEA; NORMAL HUMAN; TASTE DISORDER; VOMITING;

ADULT; ANIMALS; ANTI-INFECTIVE AGENTS; BEVERAGES; CALCIUM, DIETARY; CEREALS; CITRUS; CROSS-OVER STUDIES; FASTING; FEMALE; FOOD, FORTIFIED; FOOD-DRUG INTERACTIONS; HUMANS; MALE; MIDDLE AGED; MILK; OFLOXACIN; THERAPEUTIC EQUIVALENCY;

EID: 0043014533     PISSN: 00912700     EISSN: None     Source Type: Journal    
DOI: 10.1177/0095399703257218     Document Type: Article

References (17)

1. Food and Drug Administration: Food-Effect Bioavailability and Fed Bioequivalence Studies: Study Design, Data Analysis, and Labeling. Draft Guidance for Industry. Bethesda, MD: U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, 2001.
2. Nix DE, Watson WA, Lener M, Frost RW, Krol G, Goldstein H, et al: Effects of aluminum and magnesium antacids and ranitidine on the absorption of ciprofloxacin. Clin Pharmacol Ther 1989;46:700-705.
3. Kara M, Hasinoff BB, McKay DW, Campbell NRC: Clinical and chemical interactions between iron preparations and ciprofloxacin. Br J Clin Pharmacol 1991;31:257-261.
4. Wallace AW, Amsden GW: Is it really OK to take this with food? Old interactions with a new twist. J Clin Pharmacol 2002;42:437-443.
5. Neuhofel AL, Wilton JH, Victory JM, Hejmanowski LG, Amsden GW: Lack of bioequivalence of ciprofloxacin when administered with calcium-fortified orange juice: a new twist on an old interaction. J Clin Pharmacol 2002;42:461-466.
6. Wallace AW, Victory JM, Amsden GW: Lack of bioequivalence of gatifloxacin when co-administered with calcium-fortified orange juice in healthy volunteers. J Clin Pharmacol 2003;43:92-96.
7. Wallace AW, Victory JM, Amsden GW: Lack of bioequivalence when levofloxacin and calcium-fortified orange juice are coadministered to healthy volunteers. J Clin Pharmacol 2003;43:539-544.
8. Preston SL, Drusano GL, Berman AL, Fowler CL, Chow AT, Dornseif B, et al: Pharmacodynamics of levofloxacin: a new paradigm for early clinical trials. JAMA 1998;279:125-129.
9. Forrest A, Nix DE, Ballow CH, Goss TF, Birmingham MC, Schentag JJ: Pharmacodynamics of intravenous ciprofloxacin in seriously ill patients. Antimicrob Agents Chemother 1993;37:1073-1081.
10. Hellmich N: We're having bacon and eggs for breakfast - again. USA Today September 26, 2002;10D.
11. Schuirmann DJ: A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 1987;15:657-680.
12. Westlake WJ: Bioavailability and bioequivalence of pharmaceutical formulations, in: Westlake WJ (ed.), Biopharmaceutical Statistics for Drug Development. New York: Marcel Dekker, 1988;329-352.
13. Levaquin product information, Ortho-McNeil, 2002.
14. Takanaga H, Ohnishi A, Yamada S, Matsuo H, Morimoto S, Shoyama Y, et al: Polymethoxylated flavones in orange juice are inhibitors of P-glycoprotein but not cytochrome P450 3A4. J pharmacol Exper Ther 2000;293:230-236.
15. Yamaguchi H, Yano I, Saito H, Inui K-I: Pharmacokinetic role of P-glycoprotein in oral bioavailability and intestinal secretion of grepafloxacin in vivo. J Pharmacol Exper Ther 2002;300:1063-1069.
16. Craig WA: Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin Infect Dis 1998;26:1-12.
17. Battleman DS, Callahan M, Thaler HT: Rapid antibiotic delivery and appropriate antibiotic selection reduce length of hospital stay of patients with community-acquired pneumonia. Arch Intern Med 2002;162:682-688.